Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
Copyright policy )Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that impacts approximately 10-15% of the population in the United States and Canada. Lebrikizumab is a novel systemic human monoclonal immunoglobulin G4 antibody that inhibits the activity of interleukin-13. In June 2024, lebrikizumab was approved by Health Canada for the treatment of moderate-to-severe AD in adults and adolescents who are 12 years of age and older, followed by US Food and Drug Administration approval in September 2024. This review provides an overview of data from clinical trials on the efficacy and safety of lebrikizumab in adult patients.
- University of Calgary Canada
- University of Massachusetts Medical School United States
Adult, Canada, Adolescent, Humans, Antibodies, Monoclonal, Dermatologic Agents, Severity of Illness Index, Dermatitis, Atopic
Adult, Canada, Adolescent, Humans, Antibodies, Monoclonal, Dermatologic Agents, Severity of Illness Index, Dermatitis, Atopic
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!